We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Titan Pharmaceuticals Inc (TTNP) USD0.001

Sell:$6.51 Buy:$8.72 Change: No change
Market closed |  Prices as at close on 29 February 2024 | Switch to live prices |
Sell:$6.51
Buy:$8.72
Change: No change
Market closed |  Prices as at close on 29 February 2024 | Switch to live prices |
Sell:$6.51
Buy:$8.72
Change: No change
Market closed |  Prices as at close on 29 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing therapeutics utilizing its long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. Its ProNeura continuous drug delivery system consists of a small, solid rod-shaped implant made from a mixture of ethylene-vinyl acetate (EVA), and a drug substance. Its first product, Probuphine (buprenorphine implant), is based on ProNeura technology, which is used for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 milligrams (mg) or less a day of oral buprenorphine. Its product pipeline includes the Kappa Opioid Receptor Agonist (TP-2021) Implant and Nalmefene Implant. Its TP-2021 is used for the treatment of moderate-to-severe chronic pruritus. Its Nalmefene Implant is used for the prevention of relapse in opioid use disorder (OUD) patients following detoxification from opioids.

Contact details

Address:
SUITE 505, 400 OYSTER POINT BLVD
SAN FRANCISCO
94080
United States
Telephone:
+1 (415) 2444990
Website:
https://www.titanpharm.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TTNP
ISIN:
US8883147055
Market cap:
$6.01 million
Shares in issue:
781,503
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Katherine Devarney
    President, Chief Operating Officer, Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.